Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBrief Communication

Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer

Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo and Irene J. Virgolini
Journal of Nuclear Medicine January 2023, jnumed.122.264977; DOI: https://doi.org/10.2967/jnumed.122.264977
Elisabeth von Guggenberg
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Uprimny
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian Klingler
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Warwitz
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Sviridenko
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Bayerschmidt
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianpaolo Di Santo
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene J. Virgolini
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.122.264977
DOI 
https://doi.org/10.2967/jnumed.122.264977
PubMed 
36657979

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online January 19, 2023.

Article Versions

  • You are currently viewing a previous version of this article (January 19, 2023 - 12:04).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2023 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Elisabeth von Guggenberg,
  2. Christian Uprimny,
  3. Maximilian Klingler,
  4. Boris Warwitz,
  5. Anna Sviridenko,
  6. Steffen Bayerschmidt,
  7. Gianpaolo Di Santo and
  8. Irene J. Virgolini
  1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  1. For correspondence or reprints contact: Elisabeth von Guggenberg, Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Anichstrasse 35, Innsbruck 6020, Austria. E-mail: elisabeth.vonguggenberg@tirol-kliniken.at

Statistics from Altmetric.com

Cited By...

  • 12 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
    Berthold A. Nock, Panagiotis Kanellopoulos, Lieke Joosten, Rosalba Mansi, Theodosia Maina
    Pharmaceuticals 2023 16 5
  • Advances in Radioligand Theranostics in Oncology
    Ismaheel O. Lawal, Sofiullah O. Abubakar, Honest Ndlovu, Kgomotso M. G. Mokoala, Stuart S. More, Mike M. Sathekge
    Molecular Diagnosis & Therapy 2024 28 3
  • Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer
    Thomas Günther, Nadine Holzleitner, Oliver Viering, Roswitha Beck, Georgine Wienand, Alexander Dierks, Christian H. Pfob, Ralph A. Bundschuh, Malte Kircher, Constantin Lapa, Hans-Jürgen Wester
    Journal of Nuclear Medicine 2024 65 1
  • In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study
    Christof Rottenburger, Michael Hentschel, Markus Fürstner, Lisa McDougall, Danijela Kottoros, Felix Kaul, Rosalba Mansi, Melpomeni Fani, A. Hans Vija, Roger Schibli, Susanne Geistlich, Martin Behe, Emanuel R. Christ, Damian Wild
    EJNMMI Research 2024 14 1
  • Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities
    Alessio Imperiale, Valentina Berti, Mickaël Burgy, Roberto Luigi Cazzato, Arnoldo Piccardo, Giorgio Treglia
    Reviews in Endocrine and Metabolic Disorders 2024 25 1
  • Biodistribution and Radiation Dosimetry for 68Ga-DOTA-CCK-66, a Novel CCK2R-Targeting Compound for Imaging of Medullary Thyroid Cancer
    Oliver Viering, Andreas Rinscheid, Nadine Holzleitner, Alexander Dierks, Malte Kircher, Georgine Wienand, Marianne Patt, Hans-Jürgen Wester, Ralph A. Bundschuh, Thomas Günther, Constantin Lapa, Christian H. Pfob
    Clinical Nuclear Medicine 2024 49 12
  • Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
    Giulia Santo, Gianpaolo di Santo, Francesco Cicone, Irene Virgolini
    Journal of Neuroendocrinology 2025 37 3
  • Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs
    Nadine Holzleitner, Sebastian Fischer, Isabel Maniyankerikalam, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester, Thomas Günther
    EJNMMI Research 2024 14 1
  • Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy
    Nadine Holzleitner, Meryl Vilangattil, Abir Swaidan, Clara Diaz Garcia-Prada, Marco F. Taddio, Pauline Jeanjean, Christine E. Mona, Constantin Lapa, Angela Casini, Thomas Günther, Giuseppe Carlucci
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 2
  • Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy
    Luigi Aloj, Rosalba Mansi, Stefania De Luca, Antonella Accardo, Diego Tesauro, Giancarlo Morelli
    Journal of Peptide Science 2024 30 10

Article usage

Article usage: January 2023 to April 2025

AbstractFullPdf
Jan 20231022042
Feb 2023561021
Mar 2023383012
Apr 202327508
May 202326809
Jun 202311192821
Jul 20236601418
Aug 20235991423
Sep 20234291716
Oct 20231633113
Nov 20236210024
Dec 2023475622
Jan 20246920231
Feb 20243223328
Mar 20244012464
Apr 2024497423
May 2024398836
Jun 20245110536
Jul 202410513446
Aug 202410410040
Sep 2024244126
Oct 2024302729
Nov 2024303422
Dec 2024226125
Jan 2025265929
Feb 2025267023
Mar 2025305945
Apr 2025317238
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
  • Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer
  • Google Scholar

Similar Articles

Keywords

  • Oncology: Endocrine
  • Peptides
  • PET/CT
  • cholecystokin-2 receptor
  • gallium-68
  • medullary thyroid cancer
  • minigastrin
  • Positron Emission Tomography
SNMMI

© 2025 SNMMI

Powered by HighWire